NEWS RELEASE

Evolus to Participate in Canaccord Genuity's 43rd Annual Growth Conference

7/26/2023

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will be participating in Canaccord Genuity's 43rd Annual Growth Conference in Boston.

Event: Canaccord Genuity's 43rd Annual Growth Conference
Date: Wednesday, August 9, 2023
Time: 8:30 – 8:55 am ET

An audio webcast of this event will be available on the investor relations section of Evolus' website at **www.evolus.com**. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), globally licensed under the brand name Nuceiva®. The product is manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, a line of five unique dermal fillers currently in late-stage development. Visit us at **www.evolus.com**, and follow us on **LinkedIn**, **Twitter**, **Instagram** or **Facebook**.

Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc.
Evolysse™ is a trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Investor Contact:
David K. Erickson
Vice President, Investor Relations
Tel: 949-966-1798
Email: **david.erickson@evolus.com**

Media Contact:
Email: **media@evolus.com**

Source: Evolus, Inc.